MPO and autoimmune glomerulonephritis: It is notable that we did not observe a significant effect on circulating MPO-ANCA levels following fostamatinib treatment in this study, in contrast to our previous findings in experimental autoimmune glomerulonephritis, a model of anti—glomerular basement membrane disease, in which we observed inhibition of anti–glomerular basement membrane antibody production.5